Impact of tegoprazan, a novel potassium-competitive acid blocker, on work productivity impairment and socioeconomic burden in gastroesophageal reflux disease.

Not Applicable

Not yet recruiting

• Conditions: Diseases of the digestive system

• Registration Number: KCT0009430
• Lead Sponsor: Kangdong Sacred Heart Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 27 May 2024

Recruitment & Eligibility

• Status: Not yet recruiting
• Sex: All
• Target Recruitment: 712

Inclusion Criteria

1) Those who are over 20 years of age as of the date of obtaining written consent with heartburn or gastroesophageal reflux symptoms
2) Those who have agreed to participate in the study and completed the questionnaire for this study
3) A regular worker who works for an average of 8 hours a day and 40 hours a week and is employed with a salary of at least the minimum wage (9,620 won per hour*)
* The standard of KRW 9,620 per hour under the 2023 Minimum Wage Act (can be changed depending on the application of the law based on the date of obtaining written consent)

Exclusion Criteria

1) Those who did not complete the questionnaire
2) Patients with malignancy or warning symptoms indicating malignancy (weight loss, anemia, melena, persistent vomiting, etc.)
3) a neurosis or psychotic patient undergoing psychiatric treatment
4) a dementia patient
5) Those who with chronic diseases other than high blood pressure and diabetes(asthma, chronic obstructive pulmonary disease, chronic hepatitis, cirrhosis, angina, myocardial infarction, heart failure, chronic renal failure, etc.)
6) Patient who took gastric acid inhibitors(proton pump inhibitors, H2 receptor antagonists, potassium competitive gastric acid inhibitors) within 2 weeks prior to visit 2
7) Pregnant or lactating women

Study & Design

• Study Type: Interventional Study
• Study Design: Not specified